Clinical trials for Anal cancer

92 currently recruiting clinical trials
Phase 1 / Phase 2 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer #NCT05410145 #2023-508517-16-00
Locally Advanced Metastatic Metastatic Castration-resistant KRAS G12C 1 2 3 or more
Systemic Treatment-Naive
CHU - Haut-Lévêque - Bordeaux (Pessac), CHU de Rennes - Hôpital Pontchaillou (Rennes), Gustave Roussy (Villejuif), Centre Léon Bérard (Lyon)
D3 Bio (Wuxi) Co., Ltd
Phase 1 / Phase 2 Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer #NCT06726148 #2024-517281-42-00
Phase I - cancer amplifié CCNE1
Locally Advanced Metastatic Other mutation 1 2 3 or more
Systemic Treatment-Naive
Institut de Cancérologie de l'Ouest - Site de Saint-Herblain (Saint-Herblain), Institut Bergonié (Bordeaux)
Novartis
Phase 1 / Phase 2 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer #NCT06669117 #2024-512760-64-00
Partie 1 (Escalade de dose)
Locally Advanced Metastatic Metastatic Castration-resistant MET 1 2 3 or more
Systemic Treatment-Naive
Hôpital Nord de Marseille (Marseille Cedex 20), Gustave Roussy (Villejuif), Centre Hospitalier Universitaire de Toulouse (Toulouse), Institut de Cancérologie de l'Ouest - Site de Saint-Herblain (Saint-Herblain)
Laboratoires Pierre Fabre
Phase 1 / Phase 2 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer #NCT06188702 #2025-521249-25-00
Phase 1 Dose Escalation
Locally Advanced Metastatic MTAP 1 2 3 or more
Systemic Treatment-Naive
Gustave Roussy (Villejuif), CGFL Dijon - Centre Régional De Lutte Contre Le Cancer Georges - François Leclerc (Dijon ), Institut Bergonié (Bordeaux), Hôpital de la Timone AP-HM (Marseille)
Servier
Phase 1 / Phase 2 Breast cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Bladder / Urinary Tract / Urethral cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer #NCT06188702 #2025-521249-25-00
Cohort Basket - autres tumeurs
Locally Advanced Metastatic MTAP 1 2 3 or more
Systemic Treatment-Naive
CGFL Dijon - Centre Régional De Lutte Contre Le Cancer Georges - François Leclerc (Dijon ), Institut Bergonié (Bordeaux), Gustave Roussy (Villejuif), Hôpital de la Timone AP-HM (Marseille)
Servier
Phase 1 / Phase 2 Colon cancer Rectal cancer Anal cancer Pancreas cancer #NCT06162221
Locally Advanced Metastatic KRAS G12C 1 2 3 or more
Systemic Treatment-Naive Systemic Treatment-Naive
Hôpital Foch (Suresnes), Centre François Baclesse (Caen ), IUCT Oncopôle (Toulouse), Gustave Roussy (Villejuif), Hôpital Louis Pradel (Bron ) (and 9 more...)
Revolution Medicines, Inc.
Phase 1 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer #NCT05155332 #2024-512504-19-00
Locally Advanced Metastatic Metastatic Castration-resistant 1 2 3 or more
Systemic Treatment-Naive
Centre Eugene Marquis (Rennes), Hôpital de la Timone AP-HM (Marseille), Institut Bergonié (Bordeaux), Gustave Roussy (Villejuif)
Boehringer Ingelheim
Phase 1 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer Head and neck cancer #NCT06781983
Locally Advanced Metastatic Other mutation 1 2 3 or more
Systemic Treatment-Naive
Centre Léon Bérard (Lyon), Gustave Roussy (Villejuif)
Innate Pharma
Phase 1 Breast cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer Head and neck cancer #NCT04777994
Dose d'expansion cohorte combinaison avec inhibiteur PD-1 tumeurs MSI-H
Locally Advanced Metastatic MSI/dMMR 1 2 3 or more Immunotherapy
Systemic Treatment-Naive
Centre Antoine Lacassagne (Nice), Hôpital Foch (Suresnes), IUCT Oncopôle (Toulouse), Institut Paoli-Calmettes (Marseille)
Calico Life Sciences LLC
Phase 1 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer Head and neck cancer #NCT04777994
Escalade de dose (Tumeurs solides)
Locally Advanced Metastatic 1 2 3 or more
Systemic Treatment-Naive
Centre Antoine Lacassagne (Nice), Hôpital Foch (Suresnes), IUCT Oncopôle (Toulouse), Institut Paoli-Calmettes (Marseille)
Calico Life Sciences LLC